Appointments

Request an Appointment

Cancer Answer Line:
866.223.8100

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

IRBCCTitleHospitalStagePhaseDisease
ARRY 16231113-1209 The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum (ARRAY BioPharma Inc.) Fairview, Hillcrest, Main Campus  Gynecologic
CASE 981313-662 Sentinal Lymph Node Mapping for Endometrial Cancer Main Campus  Endometrial, Gynecologic
GOG 0213CC444 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paciltaxel Alone or in Combination with Bevacizumab followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum- Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer Fairview, Hillcrest, Main Campus Phase 3Gynecologic, Ovarian
GOG 0225IRB 12-869 Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival? Main Campus  Gynecologic, Ovarian, Peritoneal
GOG 0229O13-1497 A randomized phase II study with a phase I lead-in to assess the antitumor efficacy of the MEK inhibitor Trametinib alone or in combination with GSK2141795, an AKT inhibitor in patients with recurrent or persistent endometrial cancer. Fairview, Hillcrest, Main Campus  Gynecologic
GOG 024412-1235 The lymphedema and gynecologic cancer (LEG) study: incidence, risk factors and impact of newly diagnosed patients Fairview, Hillcrest, Main Campus  Gynecologic
GOG 0260CC00126 A Phase II evaluation of Elesclomol Sodium and weekly Paclitaxel in the treatment of recurrent or persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (Sponsor: GOG, IND #110072) Main Campus Phase 2Gynecologic, Ovarian
GOG 0263CC968 Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy. Fairview, Hillcrest, Main CampusStage 1, Stage 2Phase 3Cervical, Gynecologic
GOG 0264CC906 A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advance Stage and Recurrent Chemo-Naive Sex Cord-Stromal Tumors of the Ovary Fairview, Hillcrest, Main CampusStage 2, Stage 3, Stage 4Phase 2Gynecologic, Ovarian
GOG 0274CC00194 A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone. Main Campus Phase 3Cervical, Gynecologic
GOG 027514-133 A Phase III randomized trial of pulse Actinomycin-D versus multi-day methotrexate for the treatment of low-risk gestational trophoblastic neoplasia Fairview, Hillcrest, Main Campus Phase 3Gynecologic
GOG 027912-1287 A Phase II Trial Evaluating Cisplatin and Gemcitabine Concurrent with Intensity-Modulated Radiation Therapy (IMRT) for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva Main Campus Phase 2Gynecologic
GOG 028314-851 A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND #73969) in recurrent/persistent ovary, fallopian tube, primary peritoneal, endometrial, or endometriosis-associated clear cell carcinoma characterized for the retention or loss of BAF250a Expression Fairview, Hillcrest, Main Campus  Gynecologic
GOG 0286B14-356 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Fairview, Hillcrest, Main CampusStage 3, Stage 4A, Stage 4BPhase 2, Phase 3Gynecologic
GOG 300413-1263 A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy. Fairview, Hillcrest, Main Campus Phase 3Gynecologic
GOG 9923853 A Phase I Study of Carboplatin/Paclitaxel/CTEP-Supplied Bevacizumab (NSC #704865, IND #7921) and CTEP-Supplied Agent ABT-888 (NSC#737664, IND #77840) in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube or primary peritoneal cancer Hillcrest, Main Campus Phase 1Gynecologic
GOG 992913-558 Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients with Locally Advanced Cervical Cancer Stages IB2/IIA with Positive Para-Aortic Lymph Nodes Only and Stage IIB/IIIB/IVA with Positive Lymph Node Hillcrest, Main Campus Phase 1Gynecologic

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2014 Cleveland Clinic. All rights reserved.